In vivo high-definition 3D corneal imaging

体内高清3D角膜成像

基本信息

批准号：
10602663
负责人：
Cristina Canavesi
金额：
$ 71.77万
依托单位：
LIGHTOPTECH CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-02-01 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10602663
关键词：
3-Dimensional Address Affect Anterior eyeball segment structure Area Bilateral Biopsy Blindness Cell Density Cells Cellular Structures Characteristics Clinic Clinical Clinical Data Clinical Investigator Collaborations Confocal Microscopy Cornea Corneal Diseases Data Data Collection Developing Countries Diabetes Mellitus Diagnosis Diagnostic Disease Disease Progression Dry Eye Syndromes Endothelial Cells Evaluation Eye Eye Banks Fuchs&apos Endothelial Dystrophy Future Glaucoma Goals Gold Grant Health Image Image Analysis Imaging Device Imaging Techniques Imaging technology Infection Innovation Corps Keratitis Legal patent Licensing Machine Learning Measurement Measures Methods Microscope Microscopic Microscopy Monitor Morphology Ophthalmology Optical Coherence Tomography Optics Pain Pathology Patients Persons Phase Prevalence Process Qualifying Research Resolution Retina Rights Sampling Small Business Innovation Research Grant Standardization Structure Surveys Systems Development Technology Thick Thinness Three-Dimensional Imaging Time Tissue Transplantation Tissues United States United States National Institutes of Health Universities Variant Visual Visual System Visual impairment Visualization Visually Impaired Persons aged clinical application clinical diagnosis clinical translation commercial application commercialization data acquisition data management image guided image processing imaging capabilities imaging modality imaging system improved in vivo innovation instrument instrumentation interest microscopic imaging mosaic multidisciplinary neurosensory non-invasive imaging novel novel therapeutics ocular surface phase 2 study programs prototype standard of care three-dimensional visualization tool tumor

项目摘要

The cornea, the outermost window of our visual system, is vulnerable to various types of infections and diseases. Corneal disease is one of the leading causes of visual deficiency and blindness, and is considered the second major cause of blindness in developing countries. There are nearly 5 million bilaterally corneal blind persons worldwide, and an estimated 23 million people affected by unilateral corneal blindness globally. In a conservative estimate, corneal diseases affect nearly 300,000 people in the United States, with Fuchs’ dystrophy affecting 4% of people aged over 40. Given the large prevalence of corneal disease and the near-impossibility of performing biopsy, high-definition corneal imaging is needed to assist clinical diagnosis, evaluate progression of diseases, and treatment. Additionally, the cornea is the most commonly transplanted tissue worldwide. Gabor-domain optical coherence microscopy (GDOCM) is a high-resolution, non-invasive imaging technology that can visualize microscopic structures in vivo in 3D. Preliminary data suggest that GDOCM has the following key advantages over existing corneal imaging techniques, which include specular and confocal microscopy: 1) 10-100x increase in field of view – this will lead to more accurate qualification of the corneal tissue, since a larger area can be assessed; 2) simultaneous measure of corneal thickness, quantification of endothelial cell density, as well as identification of morphological variations due to corneal disease – this will lead to full corneal evaluation in one instrument; 3) 3D imaging capability at the cellular level of the mosaic of translucent corneal cells – this will enable a detailed understanding the volumetric progression of the diseases. We have assembled an exceptionally strong team of clinical investigators to collaborate on this proposal, and with their help we have identified four use cases for clinical application of our dual-imaging technology to image the cornea with volumetric cellular-resolution. We envision that in the future the dual OCT (optical coherence tomography) and GDOCM instrument enabled by this Phase II SBIR proposal will provide an image-guidance method to assist clinicians in the assessment and treatment of corneal diseases and other diseases affecting the anterior segment of the eye, including diabetes and glaucoma.

角膜是我们视觉系统最外层的窗口，很容易受到各种类型的感染和疾病的影响。角膜疾病是导致视力缺陷和失明的主要原因之一，被认为是第二大原因发展中国家失明的主要原因有近 500 万双眼角膜失明者。据保守估计，全球有 2300 万人受到单眼角膜失明的影响。据估计，美国有近 30 万人患有角膜疾病，其中福克斯营养不良症影响了 4% 的 40 岁以上人群。考虑到角膜疾病的广泛流行以及几乎不可能的治疗进行活检时，需要高清角膜成像来协助临床诊断、评估病情进展此外，角膜是全世界最常见的移植组织。 Gabor 域光学相干显微镜 (GDOCM) 是一种高分辨率、非侵入性成像技术可以以 3D 形式可视化体内微观结构。初步数据表明，GDOCM 具有以下特点。与现有角膜成像技术（包括镜面和共焦显微镜）相比的主要优势：1) 视野增加 10-100 倍 – 这将导致角膜组织的鉴定更加准确，因为更大的视野可以评估面积；2）同时测量角膜厚度，量化内皮细胞密度，以及识别由于角膜疾病引起的形态变化——这将导致全面的角膜评估在一台仪器中；3) 半透明角膜细胞镶嵌的细胞水平的 3D 成像能力将使人们能够详细了解疾病的体积进展。我们组建了一支非常强大的临床研究团队来就这项提案进行合作，并且在他们的帮助下，我们确定了双成像技术临床应用的四个用例我们设想未来的双 OCT（光学相干性）。第二阶段 SBIR 提案启用的 GDOCM 仪器将提供图像引导协助评估和治疗角膜疾病和其他影响角膜疾病的方法眼前节，包括糖尿病和青光眼。